AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$1.08 USD
0.00 (0.00%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.10 +0.02 (1.85%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
AN2 Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ANTX 1.08 0.00(0.00%)
Will ANTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANTX
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why
ANTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANTX
ANTX: AN2 Therapeutics Partners on Chagas Disease Oral Treatment | ANTX Stock News
AN2 Therapeutics, DNDi collaborate on development of AN2-502998
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to ...
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute ...
AN2 Therapeutics completes 200-patient observational study in acute melioidosis